Simulations Plus (NASDAQ:SLP) Issues FY 2024 Earnings Guidance

Simulations Plus (NASDAQ:SLP) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided EPS guidance of 0.540-0.560 for the period, compared to the consensus EPS estimate of 0.550. The company issued revenue guidance of $69.0 million-$72.0 million, compared to the consensus revenue estimate of $70.9 million. Simulations Plus also updated its FY24 guidance to $0.54-0.56 EPS.

Simulations Plus Stock Performance

SLP stock opened at $39.89 on Friday. Simulations Plus has a one year low of $32.69 and a one year high of $52.69. The company’s fifty day moving average price is $47.56 and its 200-day moving average price is $44.12. The company has a market capitalization of $797.40 million, a PE ratio of 75.26 and a beta of 0.72.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Tuesday, July 2nd. The technology company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.15 by $0.04. Simulations Plus had a net margin of 14.36% and a return on equity of 7.80%. The firm had revenue of $18.54 million for the quarter, compared to the consensus estimate of $17.92 million. During the same quarter in the previous year, the firm earned $0.20 earnings per share. The company’s quarterly revenue was up 14.2% compared to the same quarter last year. On average, research analysts predict that Simulations Plus will post 0.55 EPS for the current fiscal year.

Simulations Plus Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, August 5th. Investors of record on Monday, July 29th will be paid a dividend of $0.06 per share. This represents a $0.24 dividend on an annualized basis and a yield of 0.60%. The ex-dividend date of this dividend is Monday, July 29th. Simulations Plus’s payout ratio is 45.28%.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SLP. Oppenheimer upped their price target on shares of Simulations Plus from $55.00 to $65.00 and gave the company an outperform rating in a research note on Thursday, June 13th. Craig Hallum reiterated a buy rating and set a $56.00 price objective on shares of Simulations Plus in a research report on Wednesday. Finally, William Blair assumed coverage on shares of Simulations Plus in a research report on Friday, June 28th. They set an outperform rating on the stock.

Insider Buying and Selling at Simulations Plus

In other Simulations Plus news, Director Daniel L. Weiner sold 3,250 shares of the business’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $48.31, for a total transaction of $157,007.50. Following the transaction, the director now owns 8,759 shares in the company, valued at $423,147.29. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Daniel L. Weiner sold 750 shares of the company’s stock in a transaction dated Friday, June 28th. The shares were sold at an average price of $49.32, for a total value of $36,990.00. Following the transaction, the director now directly owns 7,009 shares in the company, valued at $345,683.88. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel L. Weiner sold 3,250 shares of the company’s stock in a transaction dated Tuesday, May 7th. The stock was sold at an average price of $48.31, for a total transaction of $157,007.50. Following the completion of the transaction, the director now owns 8,759 shares in the company, valued at $423,147.29. The disclosure for this sale can be found here. Insiders have sold 44,500 shares of company stock worth $2,072,198 over the last quarter. Insiders own 20.90% of the company’s stock.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.